Business Context and Reporting Period
This Form 6-K filing is submitted by Galapagos NV (not Lakefront Biotherapeutics NV as indicated in metadata) for the month of January 2021. The filing serves to incorporate by reference a press release dated January 21, 2021, regarding a material event. Galapagos NV is a foreign private issuer incorporated in Belgium.
Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This document is a procedural filing to distribute a press release and does not contain a financial statement or quarterly results summary.
Material Changes
The filing references a press release (Exhibit 99.1) issued on January 21, 2021, which contains the material event. The text of the press release is not included in the provided input, so specific material changes cannot be summarized. The filing notes that the press release is incorporated into the company's Registration Statements on Forms F-3 and S-8.
Guidance, Outlook, and Risks
The filing text does not contain management commentary, financial guidance, outlook, or specific risk factors. It explicitly excludes a quote by Mr. Onno van de Stolpe from the incorporation by reference, though the quote itself is not provided in the text.
Key Facts for Investor Verification
- Verify the content of the press release dated January 21, 2021 (Exhibit 99.1), as the specific material event is not detailed in this filing text.
- Confirm the registrant is Galapagos NV, a Belgian entity, despite metadata suggesting Lakefront Biotherapeutics NV.
- Note that this filing incorporates the press release into active Registration Statements (Forms F-3 and S-8).
- Check for the excluded quote by Mr. Onno van de Stolpe in the original press release if relevant to the material event.